13 not yet recruiting, 9 recruiting. 18 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Not yet recruiting 12, Recruiting 6 |
| Phase 3 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Becotatug Vedotin: new trials by email Literature Review of Becotatug Vedotin trials Research Report on Becotatug Vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Becotatug Vedotin - Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Kai Hu | 140 | 2026-09-01 | 2026-06-09 |
| A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma Pucotenlimab, Becotatug vedotin, Radiotherapy - LA HNSCC | Phase 2 | Not yet recruiting | Jiangsu Cancer Institute & Hospital | 35 | 2026-08-31 | 2026-07-16 |
| Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive Becotatug Vedotin, Pucotenlimab - Advanced Refractory Solid Tumors, EGFR Gene Overexpression | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 32 | 2026-08-01 | 2026-07-17 |
| Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II Becotatug Vedotin, Tislelizumab, Lenvatinib - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 36 | 2026-08-01 | 2026-07-16 |
| Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Hongmeng Yu | 25 | 2026-08-01 | 2026-08-24 |
| EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer Becotatug Vedotin, Pucotenlimab - Penile Cancer | Phase 2 | Recruiting | Jiyan Liu | 60 | 2026-07-22 | 2026-07-29 |
| A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | West China Hospital | 90 | 2026-07-20 | 2026-09-11 |
| Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer Pucotenlimab, Becotatug vedotin, Radiotherapy - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 39 | 2026-07-15 | 2026-06-04 |
| Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II Becotatug Vedotin, Pucotenlimab - Biliary Tract Cancer (BTC), EGFR-positive Advanced Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | HuiKai Li | 30 | 2026-07-01 | 2026-06-16 |
| Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer Becotatug Vedotin, Cetuximab - RAS Wild Type mCRC | Phase 2 | Not yet recruiting | Fudan University | 31 | 2026-06-01 | 2026-03-24 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations Becotatug Vedotin, Pucotenlimab, Gemcitabine - Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 164 | 2026-05-20 | 2026-05-20 |
| Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study Becotatug Vedotin, Pucotenlimab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 42 | 2026-05-01 | 2026-05-15 |
| ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan - Adenoid Cystic Carcinoma of the Head and Neck, SBRT | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-05-01 | 2026-05-12 |
| A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma Becotatug Vedotin - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 40 | 2026-04-28 | 2026-07-28 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Becotatug Vedotin, Toripalimab, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-04-20 | 2026-04-29 |
| Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 Tislelizumab, Becotatug Vedotin, Cisplatin - ESCC, Tislelizumab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 93 | 2026-04-01 | 2026-04-15 |
| Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Gemcitabine + cisplatin (GP) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 514 | 2026-04-01 | 2026-04-13 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-03-05 | 2026-03-16 |
| Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy Becotatug vedotin - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Recruiting | Sun Yat-sen University | 59 | 2026-02-10 | 2026-04-13 |
Showing 20 of 22. Sign in to see all of them.
Nasopharyngeal Carcinoma (5) · Squamous Cell Carcinoma of Head and Neck (3) · Biliary Tract Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Medulloblastoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Penile Neoplasms (1) · Recurrence (1) · Rhabdoid Tumor (1)
Sun Yat-sen University (5) · Fudan University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Anhui Provincial Cancer Hospital (1) · Eye & ENT Hospital of Fudan University (1) · First Affiliated Hospital of Guangxi Medical University (1) · Hongmeng Yu (1) · HuiKai Li (1) · Jiangsu Cancer Institute & Hospital (1) · Jiyan Liu (1) · Kai Hu (1) · Ming-Yuan Chen (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sir Run Run Shaw Hospital (1) · Tianjin Medical University Second Hospital (1)
China (15)
Chunyan Chen, MD, PhD (1) · Haitao Wang, Ph.D. (1) · Hongmeng Yu (1) · Kai Xue (1) · Li Yan (1) · Mingyuan Chen (1) · Quan Liu (1) · Xiaole Song (1) · Xuekui Liu, MD, PhD (1) · Yi-Jun Hua, MD (1)
PMID 12112535, PMID 17761983, PMID 17960615, PMID 37097003, PMID 39097677, PMID 42757773